BANKA BIO
CONSERVING YOUR FUTURE

Registered Office: A-109 Express Apartments, Lakdi ka Pool, Hyderabad - 500004
Corporate Office: 5th floor, Prestige Phoenix, 1405, Uma Nagar, Begumpet, Hyderabad - 500016
+91 7780301502 • info@bankabio.com • www.bankabio.com • CIN: L90001TG2012PLC082811

30 May 2023

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Outcome of Board Meeting held on 30 May 2023
Ref: Regulation 30 & 33 read with sub-para 4 & 7 of Para "A" of Part "A" of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the above-cited subject, we would like to inform you that the meeting of the Board of Directors of the Company held today i.e., Tuesday, 30 May 2023, the Board, inter alia, discussed, considered, and approved the following:

a) Audited financial results (both standalone and consolidated) for the quarter and financial year ended 31 March 2023;
b) Statement of Assets and Liabilities, Balance Sheet and Profit and Loss Account, Cash Flow Statement (both standalone and consolidated) as on 31 March 2023; and
c) Independent Auditors' Report thereon as on 31 March 2023.

These are also being made available on the website of the Company at www.bankabio.com

The meeting commenced at 12:00 PM and concluded at 2:15 PM

This is for your information and records.

Thank you

For Banka BioLoo Limited

ARCHANA ARIGELA
Digitally signed by ARCHANA ARIGELA
Date: 2023.05.30 14:22:35 +05'30'

Archana Arigela
Company Secretary & Compliance Officer
Membership No. 65613

Encld as above

BANKA BIOLOO LIMITED

Statement of STANDALONE Assets and Liabilities as at 31 March 2023

Rs. In Lacs

Particulars	Audited As at 31 March, 2023	Audited As at 31 March, 2022
ASSETS		
Non-current assets		
Property, Plant and Equipment	856.74	404.75
Capital work in progress	68.68	241.78
Right-of-use assets	146.89	202.24
Intangible assets	9.82	10.19
Financial assets		
Investments	535.76	435.76
Other financial assets	206.59	216.90
Deffered tax assets (net)	-	7.97
Other Non current assets	113.57	-
Inventories	556.35	501.64
Total non-current assets	**2,494.40**	**2,021.23**
Current assets		
Inventories	543.57	561.07
Financial assets		
Trade receivables	936.28	1,737.87
Cash and cash equivalents	82.67	29.55
Other bank balances	153.65	389.53
Loans	273.22	54.09
Other financial assets	302.64	216.20
Income tax assets	54.96	161.01
Other current assets	1,415.76	789.42
Total current assets	**3,762.75**	**3,938.74**
Total assets	**6,257.16**	**5,959.97**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,084.66	1,084.66
Other equity	2,974.28	2,660.84
Total equity	**4,058.94**	**3,745.50**
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	443.06	614.83
Lease liabilities	112.77	168.11
Provisions	28.78	29.12
Deferred tax liabilities (Net)	20.74	-
Total Non-current liabilities	**605.34**	**812.06**
Current liabilities		
Financial Liabilities		
Short-term borrowings	910.08	779.47
Trade payables		
Total outstanding dues of micro and small enterprise	-	
Total outstanding dues of creditors other than micro and small enterprise	206.72	255.49
Short- term 1ease liabilities	55.34	46.33
Other financial liabilities	35.02	14.99
Other current liabilities	385.71	306.13
Total Current liabilities	**1,592.87**	**1,402.42**
Total Equity & Liabilities	**6,257.16**	**5,959.97**

FOR & ON BEHALF OF BOARD OF DIRECTORS

VISHAL MURARKA

Digitally signed by VISHAL MURARKA
Date: 2023.05.30 14:25:23 +05'30'

Vishal Murarka

CEO & Executive Director

DIN: 06729485

Place: Hyderabad

Date: 30.05.2023

BANKA BIOLOO LIMITED

Audited STANDALONE Statement of Financial Results for the quarter & year ended 31 March 2023

S. No	Particulars	Quarter Ended			Year ended	
		Audited	Unaudited	Unaudited	Audited	Audited
		31.03.2023	31.12.2022	31.03.2023	31.03.2022	31.03.2022
1	**Income**					
	Gross Revenue from operations	1389.37	1179.39	1198.32	4825.50	4459.19
	Less:Duties & Taxes	(189.23)	(130.51)	(174.65)	(611.18)	(595.81)
	Revenue from Operations	1200.14	1048.88	1023.67	4214.32	3863.38
	Other income	41.05	15.14	10.18	81.24	45.37
	Total Income	**1241.19**	**1064.02**	**1033.85**	**4295.56**	**3908.75**
2	**Expenses**					
	Cost of materials consumed	354.41	159.36	106.02	787.29	774.66
	Changes in inventories of finished goods & work- in-progress	3.95	(7.94)	(13.64)	(29.71)	(107.80)
	Employee benefits expense	559.36	560.68	500.43	2245.29	1774.16
	Finance costs	12.17	42.21	45.62	133.16	173.13
	Depreciation and amortisation expense	56.27	27.56	27.73	143.38	94.06
	Other expenses	154.97	97.66	258.48	601.38	874.54
	Total expenses	**1141.14**	**879.53**	**924.64**	**3880.78**	**3582.75**
3	**Profit/(loss) before tax**	**100.05**	**184.49**	**109.20**	**414.78**	**326.00**
4	**Tax expense**					
	(1) Current tax	(2.64)	42.50	8.74	55.41	27.88
	(2) Taxes for earlier years	24.98	-	-	24.98	0.00
	(3) MAT Credit	-	-	-	-	0.00
	(4) Deferred tax	34.18	12.09	1.85	26.75	(7.75)
	Total Tax expense	**56.52**	**54.59**	**10.59**	**107.14**	**20.13**
5	**Profit after tax**	**43.54**	**129.90**	**98.61**	**307.64**	**305.87**
	Other comprehensive income					
	Items that will not be reclassified to profit and loss					
	Remeasurement of post-employment benefit obligations	7.76	0.00	4.51	7.76	4.51
	Income tax effect on items that will not be reclassified to	(1.95)	-	(1.10)	(1.95)	(1.10)
	Other comprehensive income for the year	**5.81**	**0.00**	**3.40**	**5.81**	**3.40**
	Total comprehensive income for the year	**49.35**	**129.90**	**102.02**	**313.44**	**309.27**
6	Paid up equity share capital (Face value Rs. 10/- each)	1084.66	1084.66	1084.66	1084.66	1084.66
7	Earnings per share					
	Basic and Diluted Earnings per share (in Rs.)	0.40	1.20	0.80	2.84	2.97
		(Not annualised)	*(Not annualised)*	*(Not annualised)*	*(Annualised)*	*(Annualised)*

FOR & ON BEHALF OF BOARD OF DIRECTORS

VISHAL MURARKA

Digitally signed by VISHAL MURARKA
Date: 2023.05.30 14:24:54 +05'30'

Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 30.05.2023

BANKA BIOLOO LIMITED

Standalone statement of Cash flows for the year ending 31.03.2023

Particulars	Year ended 31 March 2023	Year ended 31 March 2022
A. Cash flows from/(used in) operating activices		
Net profit before tax	414.78	326.00
Adjustments for:		
Depreciation and amortisation expense	143.38	94.06
Finance cost	111.54	155.63
Interest on Lease Rentals	21.62	17.50
Loss on sale of asset	-	0.25
Interest income	(81.24)	(45.37)
Operatiing profit before working capital changes	**610.08**	**548.07**
Changes in operating assets and liabilities		
(Increase)/decrease in inventories	17.50	(152.04)
(Increase)/decrease in trade receivables	801.59	(570.06)
(Increase)/decrease in other financial assets	(76.13)	295.40
(Increase)/decrease in other current assets	(626.34)	(179.80)
(Increase)/decrease in other non-current assets	(113.57)	47.71
(Increase)/decrease in other non-current inventory	(54.71)	(107.64)
(Increase)/decrease in other current assets-Loans given	(219.13)	(54.09)
(Increase)/decrease in other assets	110.23	(2.20)
Increase/(Decrease) in trade payables	(48.77)	6.78
Increase/(Decrease) in other financial liabilities	20.03	4.82
Increase/(Decrease) in other current liabilities	79.58	133.37
Increase/(Decrease) provisions	7.42	0.86
Cash (used in)/from operating activities	**507.78**	**(28.82)**
Tax paid	84.57	66.68
Net cash (used in)/ from operating activities	**423.21**	**(95.50)**
B.Cash flow from/(used in) investing activity		
Purchase of fixed assets	(366.54)	(316.04)
Sale of Asset	-	0.70
(Increase)/decrease in investments	(100.00)	1.00
Interest received	81.24	45.37
Net cash (used in)/from investing activities	**(385.31)**	**(268.97)**
C. Cash flows from/(used in) financing activities		
Repayment /proceeds of long term borrowings	(171.77)	28.02
Increase/(decrease) in short term borrowing	130.61	308.09
Payment of principle portion of lease liabilities	(67.96)	(44.05)
Interest paid	(111.54)	(155.63)
Dividend paid	-	-
Net cash (used in)/from financing activities	**(220.66)**	**136.42**
Net increase /(decrease) in cash and cash equivalents	**(182.76)**	**(228.05)**
Add: Cash and cash equivalents at the beginning of the year	419.08	647.13
Less: Bank deposits with less than 12 months maturity	153.65	389.53
Cash and cash equivalents at the end of the year	**82.67**	**29.55**

FOR & ON BEHALF OF BOARD OF DIRECTORS

VISHAL MURARKA

Digitally signed by VISHAL MURARKA
Date: 2023.05.30 14:25:11 +05'30'

Vishal Murarka

CEO & Executive Director

DIN: 06729485

Place: Hyderabad

Date: 30.05.2023

Notes:

1. The above audited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 30 May 2023.

2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") followed consistently and other accounting principles generally accepted in India. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.

3. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to the business of waste water & fecal treatment manufacture, supply and installation of and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".

4. The figures of the quarter ended March are the balancing figures between audited figures in respect of full financial year up to March and the unaudited published year to date figures up to December of each year, being the date of the end of third quarter of respective financial years which were subject to limited review.

5. During the financial year ended 31st March 2018, the company has completed its initial public Offer (IPO) of 10,98,000 Equity Shares of Rs.10/- each at a price of Rs.115 per share (including a premium of Rs.105 per share).

6. Proceeds from Initial Public Offer of Equity Shares have been utilized as under:

S. No	Particulars	Projected Utilization of Funds as per Prospectus	Actual Utilization of Funds till 31.03.2023	Deviation/ Variation (if any)
1	Long Term Working Capital Requirement	797.88	797.88	
2	General Corporate Purpose	231.62	231.62	
3	Issue Related Expenses-Company portion	61.10	61.08	
4	Capital expenditure at existing inoculum at Aler	75.21	75.21	
5	Capital expenditure at proposed new unit at Ibrahimpatnam	96.89	96.89	
	Total	**1,262.70**	**1262.70**	**-**

7. The revenue for the year includes unbilled revenue of Rs.1263.19 lac (previous year Rs.728.71 lac) pending for customers' final inspection. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.

8. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For **Banka Bioloo Limited**

VISHAL MURARKA Digitally signed by VISHAL MURARKA Date: 2023.05.30 14:16:22 +05'30'

Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 30 May 2023

BANKA BIOLOO LIMITED

Statement of CONSOLIDATED Assets and Liabilities as at 31 March 2023

In Lakhs

Particulars	Audited As at 31 March , 2023	Audited As at 31 March, 2022
ASSETS		
Non-current assets		
Property, plant and equipment	879.95	432.67
Capital work in progress	343.25	241.78
Right-to-use asset	146.89	202.24
Intangible assets	9.82	10.19
Goodwill on consolidation	31.51	31.51
Financial assets	-	-
Investments	5.65	5.01
Other financial assets	285.45	217.53
Deffered tax assets (net)	-	6.94
Other non-current assets	113.57	-
Inventories	556.35	501.64
Total non-current assets	**2,372.45**	**1,649.52**
Current assets		
Inventories	872.10	838.93
Financial assets	-	-
Trade receivables	1,169.98	2,035.93
Cash and cash equivalents	84.07	31.92
Other bank balances	174.53	396.11
Loans	21.84	27.57
Other financial assets	438.88	259.13
Income tax assets	54.96	190.67
Other current assets	1,331.93	975.66
Total current assets	**4,148.30**	**4,755.92**
Total assets	**6,520.74**	**6,405.43**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,084.66	1,084.66
Other equity	2,925.24	2,665.53
Equity attributable to shareholders of the company	**4,009.89**	**3,750.19**
Non-controlling interests	-	-
Total equity	**4,009.89**	**3,750.19**
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	493.90	742.91
Lease liabilities	112.77	168.11
Provisions	28.78	29.12
Deferred tax liabilities (Net)	21.66	-
Total Non-current liabilities	**657.11**	**940.14**
Current liabilities		
Financial Liabilities		
Short-term borrowings	1,009.48	892.25
Trade payables	-	-
Total outstanding dues of micro and	-	-
small enterprises	58.55	70.64
Total outstanding dues of creditors	-	-
other than micro and small enterprises	256.04	295.29
Lease liabilities	55.34	46.33
Other financial liabilities	165.40	18.65
Other current liabilities	308.93	391.94
Total Current liabilities	**1,853.74**	**1,715.11**
Total Equity & Liabilities	**6,520.74**	**6,405.43**

FOR & ON BEHALF OF BOARD OF DIRECTORS

VISHAL MURARKA Digitally signed by VISHAL MURARKA Date: 2023.05.30 14:15:27 +05'30'

Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 30.05.2023

BANKA BIOLOO LIMITED

Audited CONSOLIDATED Statement of Financial Results for the quarter & year ended 31 March 2023

In Lakhs

S. No	Particulars	Quarter ended			Year ended	Year ended
		31.03.2023 Audited	**31.12.2022 Unaudited**	**31.03.2022 Unaudited**	**31.03.2023 Audited**	**31.03.2022 Audited**
1	**Income**					
	Revenue from Operations	818.28	1,070.68	1,035.37	4,234.98	3,875.08
	Other income	34.89	10.50	10.18	70.11	45.37
	Total Income	**853.16**	**1,081.18**	**1,045.55**	**4,305.09**	**3,920.45**
2	**Expenses**					
	Cost of materials consumed	(54.29)	137.69	110.03	593.21	778.67
	Changes in inventories of finished goods & work- in-progress	3.46	(4.38)	(12.38)	(39.35)	(106.54)
	Employee benefits expense	588.13	588.04	502.69	2,370.09	1,776.42
	Finance costs	17.62	47.01	46.28	154.81	173.78
	Depreciation and amortisation expense	57.68	28.66	27.81	148.25	94.15
	Other expenses	174.56	127.24	259.73	716.31	875.79
	Total expenses	**787.14**	**924.27**	**934.16**	**3,943.32**	**3,592.27**
3	Share of profit/(loss) of Associates	(6.70)	4.17	4.46	0.64	2.71
4	**Profit/(loss) before tax**	**59.32**	**161.08**	**115.85**	**362.41**	**330.89**
5	**Tax expense**					
	(1) Current tax	(1.17)	40.34	8.74	56.88	27.88
	(2) Taxes for earlier years	24.98	-	-	24.98	-
	(3) MAT Credit	-	-	-	-	-
	(4) Deferred tax	34.07	12.11	1.85	26.65	-7.75
	Total Tax expense	**57.88**	**52.44**	**10.59**	**108.51**	**20.13**
6	**Profit after tax**	**1.45**	**108.64**	**105.26**	**253.89**	**310.76**
	Other comprehensive income					
	Items that will not be reclassified to profit and loss					
	Remeasurement of post-employment benefit obligations	7.76	-	4.51	7.76	4.51
	Income tax effect on items that will not be reclassified	(1.95)	-	(1.10)	(1.95)	(1.10)
	Other comprehensive income for the year	**5.81**	**-**	**3.40**	**5.81**	**3.40**
	Total comprehensive income for the year	**7.25**	**108.64**	**108.66**	**259.70**	**314.17**
	Attributable to					
	Shareholders of the Company	**7.25**	**108.64**	**108.66**	**259.70**	**314.17**
	Non controlling interest	**-**	**-**	**-**	**-**	**-**
7	Paid up equity share capital (Face value Rs. 10/- each)	1,084.66	1,084.66	1,028.89	1,084.66	1,084.66
8	Earnings per share					
	Basic and Diluted Earnings per share (in Rs.)	0.07	1.00	1.02	2.39	3.02
		(Not annualised)	*(Not annualised)*	*(Not annualised)*	*(Annualised)*	*(Annualised)*

FOR & ON BEHALF OF BOARD OF DIRECTORS

VISHAL MURARKA Digitally signed by VISHAL MURARKA Date: 2023.05.30 14:15:39 +05'30'

Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 30.05.2023

BANKA BIOLOO LIMITED

Consolidated statement of Cash flows for the period ending 31.03.2023 **In Lakhs**

Particulars	Period ended 31.03.2023	Year ended 31 March 2022
A. Cash flows from/(used in) operating activices		
Net profit before tax	362.41	330.89
Adjustments for:	-	-
Depreciation and amortisation expense	148.25	94.15
Finance cost	133.19	156.29
Interest on Lease Rentals	21.62	17.50
Loss on sale of asset	-	0.25
Interest income	(70.11)	(45.37)
Operatiing profit before working capital changes	**595.36**	**553.70**
Changes in operating assets and liabilities		
(Increase)/decrease in inventories	(33.18)	(152.04)
(Increase)/decrease in trade receivables	865.95	(570.06)
(Increase)/decrease in other financial assets	(247.66)	295.40
(Increase)/decrease in other current assets	(356.27)	(233.89)
(Increase)/decrease in other non-current assets	(113.57)	47.71
(Increase)/decrease in non-current inventory	(54.71)	(107.64)
(Increase)/decrease in other assets	144.15	(2.20)
Increase/(Decrease) in trade payables	(51.34)	6.78
Increase/(Decrease) in other financial liabilities	146.74	49.41
Increase/(Decrease) in other current liabilities	(83.01)	134.69
Increase/(Decrease) provisions	7.42	0.86
Cash (used in)/from operating activities	**819.88**	**22.72**
Tax paid	84.57	66.68
Net cash (used in)/ from operating activities	**735.31**	**(43.96)**
B.Cash flow from/(used in) investing activity		
Purchase of fixed assets	(641.28)	(316.04)
Sale of Asset	-	0.70
(Increase)/decrease in investments	(0.64)	(1.68)
Interest received	70.11	45.37
Net cash (used in)/from investing activities	**(571.81)**	**(271.65)**
C. Cash flows from/(used in) financing activities		
Repayment /proceeds of long term borrowings	(249.01)	28.02
Increase/(decrease) in short term borrowing	117.23	267.16
Payment of lease liabilities	(67.96)	(44.05)
Interest paid	(133.19)	(155.63)
Dividend paid		-
Net cash (used in)/from financing activities	**(332.92)**	**95.50**
Net increase /(decrease) in cash and cash equivalents	**(169.43)**	**(220.12)**
Add: Cash and cash equivalents at the beginning of the year	428.03	648.14
Less: Bank deposits with less than 12 months maturity	174.53	396.11
Cash and cash equivalents at the end of the year	**84.07**	**31.92**

For and on behalf of Board of Directors

VISHAL MURARKA Digitally signed by VISHAL MURARKA Date: 2023.05.30 14:15:51 +05'30'

Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 30.05.2023

Notes:

1. The above statement of Audited Consolidated Financial Results was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 30 May 2023.

2. These Consolidated Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") followed consistently and other accounting principles generally accepted in India. These Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.

3. The consolidated financial results of the Group include the results of the Company and results of the following entities.

Name of the entity	Status
Enzotech Solutions Pvt Ltd	Wholly owned subsidiary
Megaliter Varunaa Pvt Ltd	Wholly owned subsidiary
Sai Banka SPV Pvt Ltd	Associate with 50% share to the Company
Sustainable Sanitation Industry Association	Associate with 25% share to the Company

4. The figures of the quarter ended March are the balancing figures between audited figures in respect of full financial year up to March and the unaudited published year to date figures up to December of each year, being the date of the end of third quarter of respective financial years which were subject to limited review. Consequently, the cost of materials consumed is reported with a negative figure.

5. The revenue for the year includes unbilled revenue of Rs.1464.45 lac (previous year Rs.841.57 lac) pending for customers' final inspection. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.

6. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For **Banka Bioloo Limited**

VISHAL MURARKA Digitally signed by VISHAL MURARKA Date: 2023.05.30 14:16:39 +05'30'

Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 30 May 2023

P R S V & Co. LLP
Chartered Accountants

202, Saptagiri Residency,
1-10-98/A, Chikoti Gardens,
Begumpet, Hyderabad - 500 016
Phone : +91 40 66108177/2776 6881
Telefax : +91 40 2776 6881
E-mail : prsvco@gmail.com
Website : prsvllp.com

Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors of
BANKA BIOLOO LIMITED

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying Statement of Audited Standalone Financial Results of BANKA BIOLOO LIMITED ("the Company) for the quarter and year ended 31st March 2023 ("The Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended.

In our opinion and to the best of our information and according to the explanations given to us, the statement:

a) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

b) Gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India of the standalone net profit and other comprehensive income and other financial information of the Company for the quarter and year ended 31st March, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

PRSV & CO. LLP Hyderabad FRN:S-200016 Chartered Accountants

Responsibilities of Management for the Standalone Financial Results

The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone financial statements which has been prepared in accordance with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 if the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statements, Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

a) Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.

c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

Hyderabad
FRN:S-200016
Chartered Accountants

If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

e) Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the Quarter ended 31st March 2023 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.

For PRSV & Co. LLP
Chartered Accountants
Firm's Registration No. S200016

PRSV & CO. LLP
Hyderabad
FRN:S-200016
Chartered Accountants

Raja Praturi
Partner
Membership No.020615

UDIN: 23020615BGYNOA5537

Place: Hyderabad
Date: 30 May 2023

P R S V & Co. LLP
Chartered Accountants

202, Saptagiri Residency,
1-10-98/A, Chikoti Gardens,
Begumpet, Hyderabad - 500 016
Phone : +91 40 66108177/2776 6881
Telefax : +91 40 2776 6881
E-mail : prsvco@gmail.com
Website : prsvllp.com

Independent Auditor's Report on the Quarterly and Year to Date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended

TO
THE Board of Directors of
BANKA BIOLOO LIMITED

Report on the Audit of the Consolidated Financial Results

Opinion

We have audited the accompanying statement of audited consolidated financial results of BANKA BIOLOO LIMITED ("the Holding Company) its wholly owned subsidiary entities and associates for the quarter and year ended 31st March 2023 ("the statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended.

In our opinion and to the best of our information and according to the explanations given to us, the Statement

a) Includes the results of the following entities
Holding Company
Banka Bioloo Limited

Wholly owned subsidiary
Enzotech Solutions Pvt Ltd
Megaliter Varunaa Pvt Ltd

Associates
a. Sai Banka SPV Pvt Ltd., with a share of 50% to the holding company
b. Sustainable Sanitation Industry Association with a share of 25% to the holding company

b) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, and

c) Gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India of the consolidated net profit and other comprehensive income and other financial information of the Company for the quarter and year ended 31st March, 2023.

PRSV & CO. LLP Hyderabad FRN:S-200016 Chartered Accountants

a) Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.

c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

d) Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group of which we are the independent auditors and whose financial information we have audited, to express an opinion on the Statement. We are responsible for the direction, supervision, and performance of the audit of the financial information of such entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

e) Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

1. We did not audit the financial statements/financial information of wholly owned subsidiary viz., Enzotech Solultions Pvt. Ltd., included in the consolidated financial results, whose financial statements/financial information reflects total assets of Rs.1106.91 lakhs and total revenues of Rs. 549.61 lakhs for year ended March 31, 2023, respectively, total net loss of Rs.33.41 lakhs and total comprehensive income of Rs.33.41 lakhs for the year ended March 31, 2023. This financial statements/financial information have been audited/reviewed by other auditors whose reports have been furnished to us by the management and our opinion and conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of the said wholly owned subsidiary is solely on the reports of the other auditors and the procedures performed by us as stated under auditor's responsibilities stated above.

PRSV & Co. Hyderabad FRN:S-200016 Chartered Accountants

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management for the Consolidated Financial Statements

The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 if the Listing Regulations. The respective Board of Directors of the companies included in the group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

PRSV & CO. LLP Hyderabad FRN:S-200016 Chartered Accountants

2. We also did not audit the financial statements/financial information of two associates as mentioned above included in the consolidated financial results, the separate financial statements/financial information has been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the associates, is based solely on those statements/financials' information provided by the management and the amounts of those entities considered in the consolidated financial results are not material and significant as compared to standalone financials of the Company.

3. We audited the financial statements/financial information of wholly owned subsidiary viz., Megaliter Varunaa Pvt. Ltd., included in the consolidated financial results, whose financial statements/financial information reflects total assets of Rs.446.97 lakhs and total revenues of Rs.20.82 lakhs for year ended March 31, 2023, respectively, total net profit of Rs.1.56 lakhs and total comprehensive income of Rs.1.56 lakhs for the year ended March 31, 2023.

4. The Statement includes the results for the Quarter ended 31st March 2023 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.

For PRSV & Co. LLP Chartered Accountants
Firm's Registration No. S200016

PRSV & CO. LLP Hyderabad FRN:S-200016 Chartered Accountants

Raja Praturi
Partner
Membership No.020615

UDIN: 23020615BGYNOB2213

Place: Hyderabad
Date: 30 May 2023

BANKA BIO
CONSERVING YOUR FUTURE

Registered Office: A-109 Express Apartments, Lakdi ka Pool, Hyderabad - 500004

Corporate Office: 5th floor, Prestige Phoenix, 1405, Uma Nagar, Begumpet, Hyderabad - 500016

+91 7780301502 • info@bankabio.com • www.bankabio.com • CIN: L90001TG2012PLC082811

30 May 2023

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Declaration Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion

Dear Sir/Madam,

I, T V Rama Krishna, Chief Financial Officer of Banka BioLoo Limited, hereby declare that the Company's Statutory Auditors P R S V & Co. LLP, Chartered Accountants, Hyderabad, has issued an Audit Report with an un-modified opinion/ unqualified opinion, on the standalone and consolidated audited financial results for the quarter and year ended 31 March 2023.

This Declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (LODR) Regulations 2015, as amended vide its circular number CIR/CFD/CMD/56/2016 dated 27 May 2016.

This is for your information and records.

For Banka BioLoo Limited

VENKATA RAMA KRISHNA TADEPALLI
Digitally signed by VENKATA RAMA KRISHNA TADEPALLI
Date: 2023.05.30 14:32:00 +05'30'

T V Rama Krishna
CFO & Executive Director
DIN 07977695

Registered Office: A-109 Express Apartments, Lakdi ka Pool, Hyderabad - 500004
Corporate Office: 5th floor, Prestige Phoenix, 1405, Uma Nagar, Begumpet, Hyderabad - 500016
+91 7780301502 • info@bankabio.com • www.bankabio.com • CIN: L90001TG2012PLC082811

30 May 2023

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter and year ended 31 March 2023

Dear Sir/Madam,

With reference to the above-cited subject, please find enclosed herewith the statement of deviation(s) or variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter and year ended 31 March 2023.

This is for your information and necessary records.

Thank you.

For Banka BioLoo Limited

VENKATA RAMA KRISHNA TADEPALLI
Digitally signed by VENKATA RAMA KRISHNA TADEPALLI
Date: 2023.05.30 14:31:01 +05'30'

T V Rama Krishna
CFO & Executive Director
DIN 07977695

Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015

In reference to the compliance under Regulation 32(1)(a) & (b) of SEBI (LODR) Regulations, 2015, as required under regulation 32(8) of SEBI (LODR) Regulations, 2015, the Company hereby submits to National Stock Exchange, statement of deviation(s) or variation(s) for the quarter and year ended 31 March 2023.

a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable:

We, hereby, inform you that there was no deviation in the utilisation of the proceeds of the public issue from the objects stated in the prospectus of the issue, as required under regulation 32(1)(a) of SEBI (LODR) Regulations, 2015.

b) Indicating category-wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable, and the actual utilisation of funds:

We, hereby, inform that there has been no variation in the use of the proceeds from the objects stated in the prospectus dated 23 January 2018, or explanatory statement to the notice of the Extra-Ordinary Meeting dated 16 November 2017, issued for initial public offering of securities, as per Regulation 32(1)(b) of SEBI (LODR) Regulations, 2015.

Thank you.

For Banka BioLoo Limited

VENKATA RAMA KRISHNA TADEPALLI

Digitally signed by VENKATA RAMA KRISHNA TADEPALLI
Date: 2023.05.30 14:31:16 +05'30'

T V Rama Krishna
CFO & Executive Director
DIN 07977695

Annexure - A

Statement of Deviation/Variation in utilisation of funds raised

Name of listed entity	Banka BioLoo Limited
Mode of Fund Raising	Public Issue
Date of Raising Funds	5 February 2018 to 16 February 2018
Amount Raised (INR in Lakhs)	1,262.70
Report filed for Quarter ended	31 March 2023
Monitoring Agency	~~Applicable/~~ **Not Applicable**
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation/ Variation in use of funds raised	~~Yes~~/**No**
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation/ Variation	Not Applicable
Comments of the Audit Committee after review	Not Applicable
Comments of the auditors, if any	Not Applicable

Objects for which funds have been raised and where there has been a deviation, in the following table **(INR in Lakhs)**

Original Objects	**Modified Objects, if any**	**Original Allocation**	**Modified Allocation, if any**	**Funds Utilised**	**Amount of Deviation /variation for the quarter according to applicable object**	**Remarks if any**
Long-Term Working Capital Requirement	NA	797.88	NA	797.88	NA	No Deviation
General Corporate Purpose	NA	231.62	NA	231.62	NA	No Deviation
Issue Related Expenses-Company portion	NA	61.10	NA	61.08	NA	No Deviation
Capital expenditure at existing inoculum generation plant at Aler	NA	75.21	NA	75.21	NA	No Deviation
Capital expenditure at proposed new unit at Ibrahimpatnam	NA	96.89	NA	96.89	NA	No Deviation

Deviation or variation could mean:
(a) Deviation in the objects or purposes for which the funds have been raised or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
(c) Change in terms of a contract referred to in the fund-raising document i.e., prospectus, letter of offer, etc.

For Banka BioLoo Limited

VENKATA RAMA KRISHNA TADEPALLI

Digitally signed by VENKATA RAMA KRISHNA TADEPALLI
Date: 2023.05.30 14:31:25 +05'30'

Tadepalli Venkata Rama Krishna
CFO & Executive Director
DIN: 07977695

Date: 30 May 2023
Place: Hyderabad